Although HSCT is the curative treatment in most CIDs, the survival rate after HSCT is about 50% in STK4 deficiency [38], and further studies are needed to recommend HSCT as a safe therapy for patients with STK4 deficiency. This evidence concerns the gene STK4 and hyperinsulinemic hypoglycemia, familial, 4.